Corline Biomedical (CLBIO) Q2 2026 earnings summary

Executive summary

• Net sales for H1 2026 reached 8,978 KSEK, more than doubling from 4,242 KSEK in H1 2025, already surpassing full-year 2025 sales.

• The company is in an early expansion phase, driven by customer Kardium's launch of the Globe catheter in the US, Canada, and other markets.

• Positive operational and total cash flow was achieved in Q2 2026, reflecting strong cost control and financial discipline.

• Strategic focus is on scaling US market presence and supporting anticipated volume growth from Kardium.

Financial highlights

• Q2 2026 net sales: 4,687 KSEK (Q2 2025: 2,187 KSEK); H1 2026 net sales: 8,978 KSEK (H1 2025: 4,242 KSEK).

• Q2 2026 result after financial items: -1,435 KSEK (Q2 2025: -3,257 KSEK); H1 2026: -3,936 KSEK (H1 2025: -6,328 KSEK).

• Earnings per share H1 2026: -0.15 SEK (H1 2025: -0.26 SEK).

• Cash and cash equivalents at June 30, 2026: 32,994 KSEK (June 30, 2025: 8,322 KSEK).

• Equity at period end: 99,001 KSEK (80,586 KSEK); equity ratio: 86.7% (93.3%).

Outlook and guidance

• Significant sales growth expected as Kardium expands commercial presence and market penetration.

• Investment program underway to increase reagent production volume 20-fold to meet anticipated demand.

• Plan to recruit or convert 3–5 major customers to commercial phase by 2029 in prioritized market segments.